Allena Pharmaceuticals, Inc. (NASDAQ:ALNA – Get Rating) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 13,200,000 shares, an increase of 53.7% from the July 15th total of 8,590,000 shares. Based on an average trading volume of 31,420,000 shares, the days-to-cover ratio is currently 0.4 days.
Allena Pharmaceuticals Stock Performance
Shares of NASDAQ:ALNA opened at $0.12 on Friday. The firm has a fifty day moving average price of $0.14 and a 200 day moving average price of $0.23. Allena Pharmaceuticals has a fifty-two week low of $0.07 and a fifty-two week high of $1.17.
Get Allena Pharmaceuticals alerts:Allena Pharmaceuticals (NASDAQ:ALNA – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.07. Research analysts expect that Allena Pharmaceuticals will post -0.31 earnings per share for the current fiscal year.
About Allena Pharmaceuticals
(Get Rating)Allena Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease.
Featured Articles
- Get a free copy of the StockNews.com research report on Allena Pharmaceuticals (ALNA)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.